Transcriptomic profiling of mouse primary BCC tumor-derived organoids following Il1a and Osm combination treatment demonstrated genome-wide changes consistent with those observed in mouse BCC cell line (Supplementary Figs. 7a, b). This evidence concerns the gene IL1A and skin basal cell carcinoma.